Clinical Trial: Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053059) titled 'Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)' on June 30.

Brief Summary: The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.

Study Start Date: Dec. 01, 2025

Study Type: INTERVENTIONAL

Condition: Acute Lymphocytic Leukemia (ALL)

Intervention: DRUG: Obecabtagene autoleucel

given by Infusion

Re...